44.4 2020 Year In Review: How Patients and Patient Advocates reacted to a year of lows and high
Send us a text Wayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exciting paths for new agents and non-invasive testing. Wayne Eskridge describes his excitement as 2020 ends, saying "The quality of the work that's being done overall says that this is a far more tractable problem than we thought it was a couple of years ago. The level of sophistication that's being applied was undreamed of by the profession ...
1 Jan 202123min
44.3 2020 Year In Review: Revisiting the "MAFLD vs. NAFLD" debate
Send us a text Louise Campbell questions the implication of APASL and ALEH endorsing "MAFLD" as Fatty Liver Disease nomenclature and Stephen Harrison discusses behind-the-scenes activities to resolve this issue. Louise Campbell "wonders" where increased support for adopting the term "MAFLD" (Metabolic-Associated Fatty Liver Disease) instead of NAFLD (Non-Alcoholic Fatty Liver Disease) "is going to take us in the next 12 months and how we are going to come to a resolution." In response Stephe...
1 Jan 202118min
44.2 2020 Year In Review: Fatty Liver Disease Enters the Public Dialogue in Germany
Send us a text Joern Schattenberg discusses the public health implications of German newspapers beginning to discuss Fatty Liver Disease For Joern Schattenberg, reading about Non-Alcoholic Fatty Liver Disease in a German newspaper "has two or three very important implications that we have discussed on the podcast in the past year," particularly in terms of educating patients with metabolic syndromes and families with obese children or adolescents. Increasing awareness of late-stage liver fib...
1 Jan 202121min
44.1 2020 Year in Review: Simplifying NASH Diagnostics Saves Money, improves satisfaction
Send us a text Ian Rowe discusses how streamlined use of ELF, FIB-4 and FibroScan improves cost effectiveness and patient satisfaction associated with NASH screening. Ian Rowe comments on data from the landmark work he, Richard Parker and colleagues in Leeds, UK are conducting around the issue of population screening for NASH: "it's quite easy to show that you can identify more liver disease in the community and you can do so more efficiently." This short interview goes into detail.
1 Jan 202122min
2020 Year-End NASH Review 2: Patient Treatment and Perspectives
Send us a text Guests Ian Rowe, Joern Schattenberg and Wayne Eskridge join the Surfers to discuss key lessons learned in 2020 about Patient Treatment and Perspectives. Ian Rowe, Joern Schattenberg and Wayne Eskridge join the Surfers to explore some of the key lessons learned and issues uncovered in 2020. Ian Rowe discusses what population-level research in Leeds, UK, tells us about the benefits a streamlined liver testing model can yield not only in terms of better, faster diagnoses but also...
30 Dec 20201h 26min
43.4 2020 Year in Review: The Law of Unintended Consequences Blesses NASH Drug Development
Send us a text Roger Green discusses why despite widespread concerns, FDA's Complete Response Letter to Intercept did not cripple progress in NASH drug development. Observers feared that after Intercept received its CRL, investment into NASH drug development would dry up and knowledge would slow. Instead, Roger Green describes how drugs that had reached Phase 2 development maintained sufficient momentum to move forward. As a result, therapeutic focus shifted from treating fibrosis in late st...
25 Dec 202016min
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
Send us a text Stephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial drug approvals. Despite reports earlier in the year, Stephen Harrison discusses the "aggressive, conscientious effort" an array of stakeholders is making to improve on the clinical endpoints that shape the decision to approve a Fatty Liver Disease drug before it has demonstrated positive outcomes for patients and the healthcare system. Three...
25 Dec 202013min
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in fatty Liver Disease
Send us a text Mazen Noureddin describes a year in which biopsy's shortcomings are revealed at the same time as non-invasive testing becomes better and produces more robust data. Mazen Noureddin discusses the simultaneous loss of faith in biopsy as the clinical "Gold Standard" and the emergence of non-invasive tests that can become the standard and replace biopsy for three pivotal diagnostic needs: 1. Identifying patients at risk, those with fibrosis levels equal to or higher than F2 ...
25 Dec 202023min
